GENVEC ADDING THREE GENE THERAPY VECTOR APPROACHES VIA THERAGEN
Executive Summary
GENVEC ADDING THREE GENE THERAPY VECTOR APPROACHES VIA THERAGEN merger announced April 20. GenVec will be "in the unique position among gene therapy companies in its ability to screen and test gene product candidates in all four of the most widely used and studied vector systems," the company said. GenVec has been developing therapies based on in vivo delivery of adenovirus, while Theragen has been emphasizing research using the herpes simplex virus. Theragen also has conducted research with adeno- associated virus and liposomes.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth